Publicaciones en las que colabora con J. R. González Porras (17)

2022

  1. Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH–SETH

    Clinical and Translational Oncology, Vol. 24, Núm. 5, pp. 770-783

2019

  1. Identification of 58 mutations (26 Novel) in 94 of 109 symptomatic Spanish probands with protein C deficiency

    Thrombosis and Haemostasis, Vol. 119, Núm. 9, pp. 1409-1418

2017

  1. Clinical perspectives on the management of bleeding in patients on oral anticoagulants: The DECOVER Study (DElphi Consensus on oral COagulation and therapy action reVERsa

    Emergencias, Vol. 29, Núm. 1, pp. 18-26

2016

  1. Identification of new markers of recurrence in patients with unprovoked deep vein thrombosis by gene expression profiling: the retro study

    European Journal of Haematology, Vol. 97, Núm. 2, pp. 128-136

  2. Short Leukocyte Telomere Length Is Associated with Cardioembolic Stroke Risk in Patients with Atrial Fibrillation

    Stroke, Vol. 47, Núm. 3, pp. 863-865

2013

  1. Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients

    Haematologica, Vol. 98, Núm. 3, pp. 437-443

2010

  1. The role of immature platelet fraction in acute coronary syndrome

    Thrombosis and Haemostasis

2008

  1. AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms

    Haematologica, Vol. 93, Núm. 5, pp. 729-734

2007

  1. Antithrombin Cambridge II (A384S): An underestimated genetic risk factor for venous thrombosis

    Blood, Vol. 109, Núm. 10, pp. 4258-4263

  2. Hyperhomocysteinemia is a risk factor of recurrent coronary event in young patients irrespective to the MTHFR C677T polymorphism

    Thrombosis Research, Vol. 119, Núm. 6, pp. 691-698

2006

  1. A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis

    Blood, Vol. 108, Núm. 1, pp. 177-183

  2. Medium-term results of percutaneous vertebroplasty in multiple myeloma

    European Journal of Haematology, Vol. 77, Núm. 1, pp. 7-13

  3. Risk of recurrent venous thrombosis in patients with G20210A mutation in the prothrombin gene or factor V Leiden mutation

    Blood Coagulation and Fibrinolysis, Vol. 17, Núm. 1, pp. 23-28

2005

  1. CD34+ cell dose and outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation

    Leukemia and Lymphoma, Vol. 46, Núm. 2, pp. 177-183

2004

  1. Quality of life assessment in patients undergoing reduced intensity conditioning allogeneic as compared to autologous transplantation: Results of a prospective study

    Bone Marrow Transplantation, Vol. 34, Núm. 8, pp. 729-738

  2. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma

    Leukemia, Vol. 18, Núm. 4, pp. 856-863

2002

  1. Thalidomide in combination with cyclophosphamide and dexamethasone (thacydex) is effective in soft-tissue plasmacytomas [8]

    British Journal of Haematology